ClinicalTrials.gg
CompletedNCT05227053Updated Oct 23, 2026

STOP AF First Post-Approval Study

An observational study in Paroxysmal Atrial Fibrillation, sponsored by Medtronic Cardiac Ablation Solutions. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Medtronic Cardiac Ablation Solutions (part of Medtronic) · Observational

How we know

Updated Oct 23, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
142
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 84 studies in Atrial Fibrillation by Medtronic — 8 open to participants now, 12 under way, none of them phase 3. Atrial Fibrillation · Medtronic.

Enrollment
15th of 18
142 · median 777
Started
2022
with 1 other
Observational
18 of 84
2 open now
Registered
74th of 84
by date

Among the 84 studies in Atrial Fibrillation by Medtronic, this one is the 15th largest by enrollment of the 18 observational ones that give a count, is one of 2 that started in 2022, is one of 18 observational ones, and was the 74th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

8 of the 84 studies in Atrial Fibrillation by Medtronic are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Atrial Fibrillation by Medtronic, or all of them as a file.
02

Study summary

The STOP AF First PAS is a prospective, global, multi-center, observational trial.

Read the detailed description

The STOP AF First Post Approval Study (PAS) is a sub-study to the Cryo Global Registry. The STOP AF First PAS is a prospective, global, multi-center, observational trial. The purpose of the study is to describe long-term clinical performance and safety data in the recurrent symptomatic paroxysmal AF population treated with Arctic Front™ and Freezor™ MAX Families of cardiac cryoablation catheters (hereafter referred to as Arctic Front™ Cardiac Cryoablation Catheter System) as an alternative to antiarrhythmic drug therapy as an initial rhythm control strategy. This PAS is a condition of the pre-market approval order (P100010/S110) by the U.S. Food and Drug Administration.

03

Conditions studied

  • Paroxysmal Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects ≥ 18 years of age (or minimum age as required by local regulations) who have a recommendation for a pulmonary vein ablation with the Arctic Front™ cardiac cryoablation catheter System.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has been diagnosed with symptomatic paroxysmal AF
  • Subject is ≥ 18 years of age or minimum age as required by local regulations
  • Planned pulmonary vein isolation (PVI) procedure using the commercially available Arctic Front™ cardiac cryoablation catheter System.
  • Willing to comply with study requirements and give (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements

Exclusion criteria

Exclusion Criteria:

History of AF treatment with a class I or III antiarrhythmic drug, including sotalol, with the intention to prevent an AF recurrence1

. Subjects under the following conditions may be included in the study:

  1. Temporary treatment with a class I or III AAD (treatment at a therapeutic dose for a period of \<4 weeks prior to the index PVI procedure)
  2. Recent treatment with a class I or III AAD (within 6 months of the index PVI procedure) at a dose below therapeutic threshold according to the AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation
  3. A subject who has received a chemical cardioversion may be included in the study. This includes a chemical cardioversion prior to enrollment and between enrollment and ablation.

    • Subject has had a prior atrial ablation (except for cavo-tricuspid isthmus (CTI) ablation for AFL)
    • Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager
    • Subject with exclusion criteria required by local law
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
142 participants (actual)
Patient registry
No

Interventions

  • DeviceArctic Front™ Cardiac Cryoablation Catheter

    Pulmonary vein isolation will be performed with the Arctic Front™ cardiac cryoablation catheter system

06

What researchers measure

Primary outcomes

  1. Freedom from Atrial Fibrillation (AF) /Atrial Flutter (AFL) /Atrial Tachycardia (AT)

    Estimate the 36-month freedom from Atrial Fibrillation (AF) /atrial flutter (AFL) /Atrial Tachycardia (AT) recurrence using the Arctic Front™ cardiac cryoablation catheter System.

    Time frame: 36 months

  2. Freedom from Primary Safety Events

    Estimate primary safety Adverse Event (AE) rates for cryoablation using the Arctic Front™ cardiac cryoablation catheter System through 12-months.

    Time frame: 12 months

07

Study locations

11 sites
  • Alaska Heart Institute
    Anchorage, Alaska 99508, United States
  • Cardiology Associates of Fairfield County
    Stamford, Connecticut 06905-5522, United States
  • MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
  • BayCare Medical Group Cardiology
    Clearwater, Florida 33756, United States
  • Heart Rhythm Solutions
    Davie, Florida 33328, United States
  • Iowa Heart
    West Des Moines, Iowa 50266, United States
  • Southcoast Health System
    North Dartmouth, Massachusetts 02747, United States
  • Henry Ford Heart & Vascular
    Detroit, Michigan 48202-2608, United States
  • The Lindner Research Center
    Cincinnati, Ohio 45219, United States
  • Stern Cardiovascular Foundation
    Germantown, Tennessee 38138, United States
  • Texas Health Research and Education Institute
    Dallas, Texas 75231, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Sep 2026, 52 months.

Of 148 industry-sponsored observational studies under Atrial Fibrillation, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's 52 months is above that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Oct 2026 → Sep 2026 and completion Oct 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2022
First posted
Feb 7, 2022
StartActual
Apr 28, 2022
Primary completionActual
Sep 18, 2026was Oct 2026
CompletionActual
Sep 18, 2026was Oct 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 23, 2026
Primary completion
Oct 2026→Sep 18, 2026 (actual)
Oct 23, 2026
Study completion
Oct 2026→Sep 18, 2026 (actual)
Oct 23, 2026
Enrollment
200 (estimated)→142 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Active, not recruiting→Completed
    Primary completion Oct 2026→Sep 18, 2026 (now actual)
    Study completion Oct 2026→Sep 18, 2026 (now actual)
    Enrollment 200 (estimated)→142 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05227053
Responsible party
Sponsor
First posted
Feb 7, 2022
Start date
Apr 28, 2022
Primary completion
Sep 18, 2026
Completion
Sep 18, 2026
Last update
Oct 23, 2026

Study contacts

Khaldoun Tarakji, MD
study director · Medtronic CAS Chief Medical Officer

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion